Treatment of Myasthenia Gravis
暂无分享,去创建一个
[1] D. Drachman,et al. Gradually increasing doses of prednisone in myasthenia gravis. Reducing the hazards of treatment. , 1974, The New England journal of medicine.
[2] L. Zitvogel,et al. Immunomodulatory effects of cyclophosphamide and implementations for vaccine design , 2011, Seminars in Immunopathology.
[3] A. Yim,et al. Video-assisted thoracic surgery thymectomy for nonthymomatous myasthenia gravis. , 2005, Chest.
[4] D. Grob,et al. High-dose intravenous methylprednisolone in myasthenia gravis. , 1985, Archives of neurology.
[5] J. Raphael,et al. [Long-term effects of plasma exchange in myasthenia. Results of a randomized study]. , 1983, Presse medicale.
[6] M. Benatar,et al. Randomized, Double-Blind, Placebo-Controlled, Crossover, Multicenter, Phase II Study of Eculizumab in Patients with Refractory Generalized Myasthenia Gravis (gMG) (S35.004) , 2012 .
[7] I. Kulaksızoğlu,et al. Mood and Anxiety Disorders in Patients with Myasthenia Gravis , 2007, CNS drugs.
[8] G. Keynes. THE HISTORY OF MYASTHENIA GRAVIS , 1961, Medical History.
[9] J. Ulatowski,et al. Plasma exchange versus intravenous immunoglobulin treatment in myasthenic crisis , 1999, Neurology.
[10] R. Vilallonga,et al. Post-thymectomy combined treatment of prednisone and tacrolimus versus prednisone alone for consolidation of complete stable remission in patients with myasthenia gravis: a non-randomized, non-controlled study , 2007, Current medical research and opinion.
[11] I. Wirguin,et al. Acetylcholinesterase inhibitors and cholinergic modulation in Myasthenia Gravis and neuroinflammation , 2008, Journal of Neuroimmunology.
[12] S. Huson,et al. Asymptomatic maternal myasthenia as a cause of the Pena-Shokeir phenotype. , 2000, American journal of medical genetics.
[13] M. Benatar,et al. Recommendations for myasthenia gravis clinical trials , 2012, Muscle & nerve.
[14] S. Huson,et al. Teratogen update: maternal myasthenia gravis as a cause of congenital arthrogryposis. , 2000, Teratology.
[15] J. L. Lilienthal,et al. THE TREATMENT OF MYASTHENIA GRAVIS BY REMOVAL OF THE THYMUS GLAND: PRELIMINARY REPORT , 1941 .
[16] A. Vincent,et al. IgG1 antibodies to acetylcholine receptors in ‘seronegative’ myasthenia gravis† , 2008, Brain : a journal of neurology.
[17] K. Iwasa,et al. Clinical efficacy and cytokine network-modulating effects of tacrolimus in myasthenia gravis , 2008, Journal of Neuroimmunology.
[18] Robert H. Paul,et al. Fatigue and its impact on patients with myasthenia gravis , 2000, Muscle & nerve.
[19] N. Gilhus,et al. Ryanodine receptor antibodies related to severity of thymoma associated myasthenia gravis. , 1994, Journal of neurology, neurosurgery, and psychiatry.
[20] J. Griffin,et al. Mycophenolate mofetil: A safe and promising immunosuppressant in neuromuscular diseases , 2001, Neurology.
[21] W. Mccune,et al. Advances in immunosuppressive therapy. , 2007, Seminars in respiratory and critical care medicine.
[22] P. Kirschner,et al. Alfred Blalock and thymectomy for myasthenia gravis. , 1987, The Annals of thoracic surgery.
[23] E. Beghi,et al. Prognosis of myasthenia gravis: A multicenter follow-up study of 844 patients , 1991, Journal of the Neurological Sciences.
[24] J. Torner,et al. Epidemiologic evidence for a changing natural history of myasthenia gravis , 1996, Neurology.
[25] L. Durelli,et al. Actuarial analysis of the occurrence of remissions following thymectomy for myasthenia gravis in 400 patients. , 1991, Journal of neurology, neurosurgery, and psychiatry.
[26] M. Zielinski. Management of myasthenic patients with thymoma. , 2011, Thoracic surgery clinics.
[27] H. Soreq,et al. Acetylcholinesterase — new roles for an old actor , 2001, Nature Reviews Neuroscience.
[28] A. Gajra,et al. Response of myasthenia gravis to rituximab in a patient with non‐Hodgkin lymphoma , 2004, American journal of hematology.
[29] R. Barohn,et al. Myasthenia gravis , 2000, Neurology.
[30] Charles George,et al. Sleep apnea in patients with myasthenia gravis , 2006, Neurology.
[31] L. Wilkins. Assessment of plasmapheresis , 1996, Neurology.
[32] N. Schmitz,et al. Early recurrence or persistence of autoimmune diseases after unmanipulated autologous stem cell transplantation. , 1996, Blood.
[33] S. Zierz,et al. Successful treatment of MuSK antibody–positive myasthenia gravis with rituximab , 2006, Muscle & nerve.
[34] H. Kaminski,et al. The role of complement in experimental autoimmune myasthenia gravis , 2012, Annals of the New York Academy of Sciences.
[35] R. Pascuzzi,et al. THE HISTORY OF MYASTHENIA GRAVIS , 1961, Medical History.
[36] Michael H. Rivner. Steroids are overutilized , 2002 .
[37] J. Keesey. Contemporary opinions about Mary Walker , 1998, Neurology.
[38] P. Karran,et al. Thiopurines in current medical practice: molecular mechanisms and contributions to therapy-related cancer , 2008, Nature Reviews Cancer.
[39] R. Garman,et al. Subcutaneous administration of T-epitope sequences of the acetylcholine receptor prevents experimental myasthenia gravis , 1999, Journal of Neuroimmunology.
[40] M. Badri,et al. A single-blinded trial of methotrexate versus azathioprine as steroid-sparing agents in generalized myasthenia gravis , 2011, BMC neurology.
[41] R. Vilallonga,et al. Long-term results of tacrolimus in cyclosporine- and prednisone-dependent myasthenia gravis , 2005, Neurology.
[42] A. Alshekhlee,et al. Outcome of plasmapheresis in myasthenia gravis: Delayed therapy is not favorable , 2011, Muscle & nerve.
[43] P. Andrews. Treatment Algorithm for Autoimmune Myasthenia Gravis in Childhood , 1998, Annals of the New York Academy of Sciences.
[44] K. Utsugisawa,et al. Efficacy of Low-Dose FK506 in the Treatment of Myasthenia gravis – A Randomized Pilot Study , 2005, European Neurology.
[45] A. Nucci,et al. Plasmapheresis in the treatment of myasthenia gravis: retrospective study of 26 patients. , 2004, Arquivos de neuro-psiquiatria.
[46] R. Brodsky,et al. High-dose therapy for autoimmune neurologic diseases , 2005, Current opinion in oncology.
[47] D. Drachman,et al. Specific immunotherapy of experimental myasthenia gravis in vitro: the "guided missile" strategy. , 2001, Cellular immunology.
[48] PJ Mitchell,et al. Myasthenia gravis in pregnancy , 1992, Obstetrics and gynecology.
[49] P. Andrews,et al. Autoimmune Myasthenia Gravis in Childhood , 2004, Seminars in neurology.
[50] M. Benatar,et al. Evidence report : The medical treatment of ocular myasthenia ( an evidence-based review ) : Report of the Quality Standards Subcommittee of the American Academy of Neurology , 2009 .
[51] V. Armstrong,et al. New developments in the immunosuppressive drug monitoring of cyclosporine, tacrolimus, and azathioprine. , 2001, Clinical biochemistry.
[52] R. Mantegazza,et al. Azathioprine as a single drug or in combination with steroids in the treatment of myasthenia gravis , 1988, Journal of Neurology.
[53] D. Grob,et al. High-dose intravenous immunoglobulin in the management of myasthenia gravis. , 1986, Archives of internal medicine.
[54] J. Howard. Intravenous Immunoglobulin for the Treatment of Acquired Myasthenia Gravis , 1998, Neurology.
[55] R. Hohlfeld,et al. Corticosteroids for myasthenia gravis. , 2005, The Cochrane database of systematic reviews.
[56] J. Prudlo,et al. Sleep disordered breathing in medically stable patients with myasthenia gravis , 2007, European journal of neurology.
[57] R. Ben-Ami,et al. Venous and arterial thrombosis following administration of intravenous immunoglobulins , 2005 .
[58] C. Cunningham-Rundles,et al. Long-term use of IgA-depleted intravenous immunoglobulin in immunodeficient subjects with anti-IgA antibodies , 1993, Journal of Clinical Immunology.
[59] M. Walker. TREATMENT OF MYASTHENIA GRAVIS WITH PHYSOSTIGMINE , 1934 .
[60] Kirschner Pa. The history of surgery of the thymus gland. , 2000 .
[61] M. Am. Stem cell transplantation for severe autoimmune disorders, with special reference to rheumatic diseases. , 1997 .
[62] M. Benatar,et al. The importance of studying history: lessons learnt from a trial of tacrolimus in myasthenia gravis , 2011, Journal of Neurology, Neurosurgery & Psychiatry.
[63] K. Iwasa,et al. FK506 prevents induction of rat experimental autoimmune myasthenia gravis. , 1997, Journal of autoimmunity.
[64] S. Kikuchi,et al. Five-year follow-up with low-dose tacrolimus in patients with myasthenia gravis , 2011, Journal of the Neurological Sciences.
[65] J. Keesey. A Treatment Algorithm for Autoimmune Myasthenia in Adults , 1998, Annals of the New York Academy of Sciences.
[66] A. Vincent,et al. Immunology of disorders of neuromuscular transmission , 2006, Acta neurologica Scandinavica. Supplementum.
[67] B. Bergamasco,et al. Therapies for Exacerbation of Myasthenia Gravis: The Mechanism of Action of Intravenous High‐Dose Immunoglobulin G , 1993, Annals of the New York Academy of Sciences.
[68] R. Daroff. The office Tensilon test for ocular myasthenia gravis. , 1986, Archives of neurology.
[69] D. Shemin,et al. Complications of therapeutic plasma exchange: A prospective study of 1,727 procedures , 2007, Journal of clinical apheresis.
[70] H. Kaminski,et al. Disorders of Sleep and Breathing during Sleep in Neuromuscular Disease , 1999, Sleep and Breathing.
[71] J. Davis,et al. REMISSION OF MYASTHENIA GRAVIS FOLLOWING PLASMA-EXCHANGE , 1976, The Lancet.
[72] M. Mack,et al. Surgical approaches to the thymus in patients with myasthenia gravis. , 2009, Thoracic surgery clinics.
[73] J. M. Hoff,et al. Artrogryposis multiplex congenita – a rare fetal condition caused by maternal myasthenia gravis , 2006, Acta neurologica Scandinavica. Supplementum.
[74] F. Bolgert,et al. Treatment of myasthenia gravis exacerbation with intravenous immunoglobulin: a randomized double-blind clinical trial. , 2005, Archives of neurology.
[75] H. Coslett,et al. Long‐term corticosteriod treatment of myasthenia gravis: Report of 116 Patients , 1984, Annals of neurology.
[76] M. Pagala,et al. Lifetime course of myasthenia gravis , 2008, Muscle & nerve.
[77] M. Kupersmith,et al. Ocular motor dysfunction and ptosis in ocular myasthenia gravis: effects of treatment , 2005, British Journal of Ophthalmology.
[78] R. Tamler,et al. Nonsteroid Immune Modulators and Bone Disease , 2006, Annals of the New York Academy of Sciences.
[79] S. Arimori,et al. High‐Dose Gammaglobulin Therapy of Generalized Myasthenia Gravis , 1987 .
[80] F. Marsili,et al. Successful treatment of myasthenia gravis with tacrolimus , 2002, Muscle & nerve.
[81] D. Sanders,et al. Steroids have an important role , 2002 .
[82] G. Sheean,et al. Complete remission induced by rituximab in refractory, seronegative, muscle-specific, kinase-positive myasthenia gravis , 2006, Journal of Neurology, Neurosurgery & Psychiatry.
[83] R. Tindall,et al. A Clinical Therapeutic Trial of Cyclosporine in Myasthenia Gravis a , 1993, Annals of the New York Academy of Sciences.
[84] Y. Harati,et al. Immunosuppressive drug therapy in myasthenia gravis. , 1986, Archives of neurology.
[85] G. Matell,et al. [Treatment of myasthenia gravis]. , 1973, Lakartidningen.
[86] B. Eymard,et al. The Fetal/Adult Acetylcholine Receptor Antibody Ratio in Mothers with Myasthenia Gravis as a Marker for Transfer of the Disease to the Newborn , 1997, Neurology.
[87] B. Katirji,et al. Opportunistic infections in myasthenia gravis treated with mycophenolate mofetil , 2012, Journal of Neuroimmunology.
[88] Harriet Edgeworth. THE EFFECT OF EPHEDRINE IN THE TREATMENT OF MYASTHENIA GRAVIS: SECOND REPORT , 1933 .
[89] S. Leurgans,et al. Mycophenolate Mofetil for Myasthenia Gravis A Double‐Blind, Placebo‐Controlled Pilot Study , 2003, Annals of the New York Academy of Sciences.
[90] J. Lindstrom,et al. Specific killing of lymphocytes that cause experimental autoimmune myasthenia gravis by ricin toxin-acetylcholine receptor conjugates. , 1984, Journal of immunology.
[91] R. Frairia,et al. Modulation by Cytokines of Glucocorticoid Action , 1999, Annals of the New York Academy of Sciences.
[92] W. Köhler,et al. A randomized and controlled study comparing immunoadsorption and plasma exchange in myasthenic crisis , 2011, Journal of clinical apheresis.
[93] N. Molfino,et al. Use of intravenous pulsed cyclophosphamide in severe, generalized myasthenia gravis , 2002, Muscle & nerve.
[94] P. Tonali,et al. Thymoma in patients with MG , 2002, Neurology.
[95] D. Sanders,et al. Muscle autoantibodies in myasthenia gravis: beyond diagnosis? , 2012, Expert review of clinical immunology.
[96] R. Conwit,et al. The MGTX experience: Challenges in planning and executing an international, multicenter clinical trial , 2008, Journal of Neuroimmunology.
[97] A. Vandenbark,et al. TCR peptide therapy decreases the frequency of encephalitogenic T cells in the periphery and the central nervous system , 1992, Journal of Neuroimmunology.
[98] D. Sanders,et al. Update on muscle-specific tyrosine kinase antibody positive myasthenia gravis. , 2010, Current opinion in neurology.
[99] P. Tonali,et al. Course and treatment of myasthenia gravis during pregnancy , 1999, Neurology.
[100] J. Aarli,et al. Myasthenia gravis: disease severity and prognosis , 2006, Acta neurologica Scandinavica. Supplementum.
[101] B. Kim,et al. Clinical predictors of steroid-induced exacerbation in myasthenia gravis , 2006, Journal of Clinical Neuroscience.
[102] B. Källén,et al. Early pregnancy azathioprine use and pregnancy outcomes. , 2009, Birth defects research. Part A, Clinical and molecular teratology.
[103] F. Guarnieri,et al. Targeting antigen-specific T cells by genetically engineered antigen presenting cells A strategy for specific immunotherapy of autoimmune disease , 2000, Journal of Neuroimmunology.
[104] J. Dinger,et al. Arthrogryposis multiplex in a newborn of a myasthenic mother—Case report and literature , 1993, Neuromuscular Disorders.
[105] F. Mokhtarian,et al. Treatment of myasthenia gravis by immunoadsorption of plasma , 1995, Neurology.
[106] S. Lewis,et al. Osteoporosis prevention in myasthenia gravis: a reminder , 2001, Acta neurologica Scandinavica.
[107] A. Allison,et al. Mycophenolate mofetil and its mechanisms of action. , 2000, Immunopharmacology.
[108] R. Greenlee,et al. Preliminary results of a double-blind, randomized, placebo-controlled trial of cyclosporine in myasthenia gravis. , 1987, The New England journal of medicine.
[109] J. Massey,et al. Autoimmune myasthenia gravis: Recommendations for treatment and immunologic modulation , 2005, Current treatment options in neurology.
[110] W. D. Foster,et al. Experimental Staphylococcus Infection in Man , 1960 .
[111] H. Soreq,et al. The role of readthrough acetylcholinesterase in the pathophysiology of myasthenia gravis , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[112] G. Lamb,et al. Effects of FK506 and rapamycin on excitation‐contraction coupling in skeletal muscle fibres of the rat. , 1996, The Journal of physiology.
[113] J. King,et al. Immunotherapy of Ocular Myasthenia Gravis Reduces Conversion to Generalized Myasthenia Gravis , 2003, Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society.
[114] D. Sanders,et al. Mycophenolate mofetil for myasthenia gravis: An open-label pilot study , 2001, Neurology.
[115] D. Bourdette,et al. T cell receptor peptide therapy for autoimmune disease. , 1992, Journal of autoimmunity.
[116] K. Nagle,et al. Complications of intravenous immune globulin treatment in neurologic disease , 1996, Neurology.
[117] J. Parr,et al. Childhood myasthenia: clinical subtypes and practical management , 2007, Developmental medicine and child neurology.
[118] M. Kuchibhatla,et al. A Retrospective study of complications of therapeutic plasma exchange in myasthenia , 2013, Muscle & nerve.
[119] G. Koretzky,et al. Azathioprine: old drug, new actions. , 2003, The Journal of clinical investigation.
[120] M. Paul-Clark,et al. Differential modulation of glucocorticoid action by FK506 in A549 cells. , 2003, The Biochemical journal.
[121] John Newsom-Davis,et al. A randomized double‐blind trial of prednisolone alone or with azathioprine in myasthenia gravis , 1998, Neurology.
[122] W. Yoong,et al. Myasthenia gravis and pregnancy , 2007, Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology.
[123] A. Urgesi,et al. Total body irradiation for myasthenia gravis , 1993, Neurology.
[124] D. Cornblath,et al. Evidence-based guideline update: Plasmapheresis in neurologic disorders , 2011, Neurology.
[125] J. Daube,et al. ALTERNATE‐DAY PREDNISONE: PRELIMINARY REPORT OF A DOUBLE‐BLIND CONTROLLED STUDY * , 1976, Annals of the New York Academy of Sciences.
[126] L. Rowland. Controversies about the treatment of myasthenia gravis. , 1980, Journal of neurology, neurosurgery, and psychiatry.
[127] S. Chevret,et al. Clinical trial of plasma exchange and high‐dose intravenous immunoglobulin in myasthenia gravis , 1997 .
[128] S. Shimohama,et al. Early effect of tacrolimus in improving excitation–contraction coupling in myasthenia gravis , 2012, Clinical Neurophysiology.
[129] M. Cudkowicz,et al. Thromboembolic Complications of Intravenous Immunoglobulin Treatment , 2004, European Neurology.
[130] M. Hackett,et al. Incidence of Thymoma in Myasthenia Gravis: A Systematic Review , 2012, Journal of clinical neurology.
[131] J. Koo,et al. Long-term safety of mycophenolate mofetil and cyclosporine: a review. , 2008, Journal of drugs in dermatology : JDD.
[132] M. Sans,et al. Reviewing the mechanism of action of thiopurine drugs: towards a new paradigm in clinical practice. , 2004, Medical science monitor : international medical journal of experimental and clinical research.
[133] D. Perantie,et al. Corticosteroids, immune suppression, and psychosis , 2002, Current psychiatry reports.
[134] D. Lanska. Indications for thymectomy in myasthenia gravis , 1990, Neurology.
[135] J. Kirwan,et al. Glucocorticoids: action and new therapeutic insights in rheumatoid arthritis , 2007, Current opinion in rheumatology.
[136] T. Sharshar,et al. Immunosuppressive agents for myasthenia gravis. , 2007, The Cochrane database of systematic reviews.
[137] J. Dichgans,et al. Ocular myasthenia gravis: response to long-term immunosuppressive treatment. , 1997, Journal of neurology, neurosurgery, and psychiatry.
[138] P. Anderson,et al. Successful treatment of refractory myasthenia gravis using rituximab: a pediatric case report. , 2003, The Journal of pediatrics.
[139] R. D. De Abreu,et al. Reduced thiopurine methyltransferase activity and development of side effects of azathioprine treatment in patients with rheumatoid arthritis. , 1998, Arthritis and rheumatism.
[140] D. Zarembski,et al. Mycophenolate mofetil: a unique immunosuppressive agent. , 1997, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.
[141] D. Hilton‐Jones,et al. When the patient fails to respond to treatment: myasthenia gravis , 2007, Practical Neurology.
[142] B. O'neill,et al. Primary CNS lymphoma complicating treatment of myasthenia gravis with mycophenolate mofetil , 2005, Neurology.
[143] A. Echaniz-Laguna,et al. Asthma as a Cause of Persistent Dyspnea in Treated Myasthenia Gravis Patients , 2012, European Neurology.
[144] E. T. Bell. TUMORS OF THE THYMUS IN MYASTHENIA GRAVIS , 1917 .
[145] M. Baccarani,et al. Rituximab for myasthenia gravis developing after bone marrow transplant , 2000, Neurology.
[146] D. Isenberg,et al. Anti-B cell therapy (Rituximab) in the treatment of autoimmune diseases , 2005, Current opinion in pharmacology.
[147] G. Cutter,et al. Comparative analysis of therapeutic options used for myasthenia gravis , 2010, Annals of neurology.
[148] W. Tsai,et al. No increased risk of adverse pregnancy outcomes for women with myasthenia gravis: a nationwide population‐based study , 2009, European journal of neurology.
[149] A. Jimeno,et al. Mycophenolate mofetil: An update. , 2009, Drugs of today.
[150] D. Grob,et al. The Course of Myasthenia Gravis and Therapies Affecting Outcome a , 1987, Annals of the New York Academy of Sciences.
[151] G. Parry,et al. Azathioprine in the treatment of myasthenia gravis , 1984, Annals of neurology.
[152] D. Forshew,et al. Randomized trial of azathioprine or prednisone for initial immunosuppressive treatment of myasthenia gravis , 1997, Journal of the Neurological Sciences.
[153] Monica Milani,et al. Myasthenia gravis: past, present, and future. , 2006, The Journal of clinical investigation.
[154] A. Engel,et al. Ephedrine: effects on neuromuscular transmission , 1993 .
[155] S. Vorstrup,et al. Immunoglobulin treatment versus plasma exchange in patients with chronic moderate to severe myasthenia gravis. , 2001, Artificial organs.
[156] S. Fuchs,et al. A disease-specific fraction isolated from IVIG is essential for the immunosuppressive effect of IVIG in experimental autoimmune myasthenia gravis , 2008, Journal of Neuroimmunology.
[157] N. Gilhus,et al. Myasthenia gravis in pregnancy and birth: identifying risk factors, optimising care , 2007, European journal of neurology.
[158] K. Mcintosh,et al. Oral Tolerance in Myasthenia Gravis a , 1996, Annals of the New York Academy of Sciences.
[159] H. Chiu,et al. The six year experience of plasmapheresis in patients with myasthenia gravis. , 2000, Therapeutic apheresis : official journal of the International Society for Apheresis and the Japanese Society for Apheresis.
[160] D. Sanders,et al. Disorders of Neuromuscular Transmission , 2008 .
[161] L. Balcer,et al. Strategies for Treatment of Myasthenia Gravis a , 1993, Annals of the New York Academy of Sciences.
[162] D. Sanders,et al. Retrospective analysis of the use of cyclosporine in myasthenia gravis , 2000, Neurology.
[163] L. Zinman,et al. IV immunoglobulin in patients with myasthenia gravis , 2007, Neurology.
[164] V. Rakocevic-Stojanovic,et al. Cyclosporine in the treatment of myasthenia gravis , 2005, Acta neurologica Scandinavica.
[165] Harriet Edgeworth. A REPORT OF PROGRESS ON THE USE OF EPHEDRINE IN A CASE OF MYASTHENIA GRAVIS , 1930 .
[166] S. Kaveri,et al. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. , 2001, The New England journal of medicine.
[167] A. Weinacker,et al. High‐dose cyclophosphamide in refractory myasthenia gravis with MuSK antibodies , 2006, Muscle & nerve.
[168] R. Lisak,et al. “Rebooting” the immune system with cyclophosphamide: Taking risks for a “cure”? , 2003, Annals of neurology.
[169] J. Chan,et al. Mycophenolate mofetil for ocular myasthenia , 2008, Journal of Neurology.
[170] S. Huson,et al. Recurrent congenital arthrogryposis leading to a diagnosis of myasthenia gravis in an initially asymptomatic mother , 1995, Neuromuscular Disorders.
[171] J. Montoro,et al. Benefits of FK506 (tacrolimus) for residual, cyclosporin- and prednisone-resistant myasthenia gravis: one-year follow-up of an open-label study , 2005, Clinical Neurology and Neurosurgery.
[172] L. Lachenmayer,et al. [Magnetic resonance imaging in myasthenia gravis. An alternative to mediastinal computerized tomography?]. , 2008, Deutsche Medizinische Wochenschrift.
[173] S. Servidei,et al. Response to Therapy in Myasthenia Gravis with Anti‐MuSK Antibodies , 2008, Annals of the New York Academy of Sciences.
[174] I. Rogatsky,et al. Glucocorticoids and the innate immune system: Crosstalk with the Toll-like receptor signaling network , 2007, Molecular and Cellular Endocrinology.
[175] S. Chevret,et al. Plasma exchange for generalised myasthenia gravis , 2002 .
[176] J. Newsom-Davis,et al. Development of a Thymectomy Trial in Nonthymomatous Myasthenia Gravis Patients Receiving Immunosuppressive Therapy , 2003, Annals of the New York Academy of Sciences.
[177] A. McGrogan,et al. The Incidence of Myasthenia Gravis: A Systematic Literature Review , 2010, Neuroepidemiology.
[178] H. Outin,et al. High‐Dose Intravenous Gamma Globulin For Myasthenia Gravis: An Alternative to Plasma Exchange? , 1987 .
[179] K. Chapman,et al. The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights , 2011, Molecular and Cellular Endocrinology.
[180] M. Seybold. Plasmapheresis in Myasthenia Gravis , 1987, Annals of the New York Academy of Sciences.
[181] M. Perez,et al. Stable remissions in myasthenia grams , 1981, Neurology.
[182] D. Sanders,et al. Anti‐musk antibody myasthenia gravis: Clinical findings and response to treatment in two large cohorts , 2011, Muscle & nerve.
[183] J. Ravetch,et al. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. , 2001, Science.
[184] R. Conwit,et al. Status of the Thymectomy Trial for Nonthymomatous Myasthenia Gravis Patients Receiving Prednisone , 2008, Annals of the New York Academy of Sciences.
[185] L. Remen. Zur Pathogenese und Therapie der Myasthenia gravis pseudoparalytica , 1932, Deutsche Zeitschrift für Nervenheilkunde.
[186] Lorenzo Maggi,et al. Treatment of Myasthenia Gravis , 2011, Clinical drug investigation.
[187] S. Tzartos,et al. Extracellular domains of the β, γ and ε subunits of the human acetylcholine receptor as immunoadsorbents for myasthenic autoantibodies: A combination of immunoadsorbents results in increased efficiency , 2007, Journal of Neuroimmunology.
[188] A. Vincent,et al. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies , 2001, Nature Medicine.
[189] H. Zhang,et al. Clinical efficacy and immunological impact of tacrolimus in Chinese patients with generalized myasthenia gravis. , 2011, International immunopharmacology.
[190] A. Evoli. Acquired myasthenia gravis in childhood. , 2010, Current opinion in neurology.
[191] E. Segre,et al. ADRENAL SUPPRESSION BY CLOBETASOL PROPIONATE , 1975, The Lancet.
[192] W. Plauché. Myasthenia Gravis in Mothers and Their Newborns , 1991, Clinical obstetrics and gynecology.
[193] E. Brown,et al. Effects of chronic prednisone therapy on mood and memory. , 2007, Journal of affective disorders.
[194] S. Fuchs,et al. Intravenous immunoglobulin suppresses experimental myasthenia gravis: Immunological mechanisms , 2006, Journal of Neuroimmunology.
[195] T. Huizinga,et al. Recent insights in the pharmacological actions of methotrexate in the treatment of rheumatoid arthritis. , 2007, Rheumatology.
[196] G. Gronseth,et al. Practice parameter: Thymectomy for autoimmune myasthenia gravis (an evidence-based review) , 2000, Neurology.
[197] S. Liggett,et al. Ipratropium in patients with COPD receiving cholinesterase inhibitors. , 1988, Chest.
[198] D. Richman,et al. An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis , 2008, Neurology.
[199] David O. Taylor,et al. Mycophenolate mofetil and risk of developing malignancy after orthotopic heart transplantation: analysis of the transplant registry of the International Society for Heart and Lung Transplantation. , 2006, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[200] P. Tonali,et al. Quality of life in patients with myasthenia gravis , 2002, Muscle & nerve.
[201] N. Keiding,et al. Epidemiology of myasthenia gravis in Denmark. A longitudinal and comprehensive population survey. , 1991, Archives of neurology.
[202] Meier,et al. 68 Diagnostik und Therapie der Myasthenia gravis und des Lambert-Eaton-Syndroms , 2012 .
[203] J. Heckmann,et al. High-dose immunosuppressive therapy in generalised myasthenia gravis--a 2-year follow-up study. , 2001, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.
[204] J. Kissel,et al. Treatment of myasthenia gravis , 2000, Neurology.
[205] R. Vilallonga,et al. Tacrolimus for Myasthenia Gravis , 2008 .
[206] P. Tonali,et al. Health-related quality of life in patients with myasthenia gravis and the relationship between patient-oriented assessment and conventional measurements , 2001, Neurological Sciences.
[207] R. Hohlfeld,et al. Azathioprine toxicity during long‐term immunosuppression of generalized myasthenia gravis , 1988, Neurology.
[208] M. Pasnoor,et al. Clinical findings in MuSK‐antibody positive myasthenia gravis: A U.S. experience , 2010, Muscle & nerve.
[209] J. Kluin,et al. Institutional report - Thoracic general CT and myasthenia gravis: correlation between mediastinal imaging and histopathological findings , 2005 .
[210] J. Kuks,et al. Azathioprine in myasthenia gravis: Observations in 41 patients and a review of literature , 1991, Neuromuscular Disorders.
[211] A. Vincent,et al. John Newsom-Davis: clinician-scientist and so much more , 2011, Brain : a journal of neurology.
[212] D. Drachman. Myasthenia Gravis and the Thyroid Gland , 1962 .
[213] T. Kiuchi,et al. Randomised, double-blind, placebo-controlled study of tacrolimus in myasthenia gravis , 2011, Journal of Neurology, Neurosurgery & Psychiatry.
[214] V. Bril,et al. The long-term clinical outcome of myasthenia gravis in patients with thymoma , 1998, Neurology.
[215] A. Blalock,et al. MYASTHENIA GRAVIS AND TUMORS OF THE THYMIC REGION: REPORT OF A CASE IN WHICH THE TUMOR WAS REMOVED , 1939, Annals of surgery.
[216] D. Grob,et al. Adverse Cardiovascular Effects of Anticholinesterase Medications , 1987, The American journal of the medical sciences.
[217] A. Vincent,et al. Association of arthrogryposis multiplex congenita with maternal antibodies inhibiting fetal acetylcholine receptor function. , 1996, The Journal of clinical investigation.
[218] F. Rosenow,et al. Immunoadsorption in Guillain-Barré syndrome and myasthenia gravis. , 2000, Therapeutic apheresis : official journal of the International Society for Apheresis and the Japanese Society for Apheresis.
[219] M. Pescovitz. Rituximab, an Anti‐CD20 Monoclonal Antibody: History and Mechanism of Action , 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[220] V. Bril,et al. Comparison of IVIg and PLEX in patients with myasthenia gravis , 2011, Neurology.
[221] J. Massey,et al. The management of myasthenia gravis in pregnancy. , 2004, Seminars in neurology.
[222] P. Tonali,et al. Long-term results of corticosteroid therapy in patients with myasthenia gravis. , 1992, European neurology.
[223] T. Bertorini,et al. Transient neonatal myasthenia gravis in a baby born to a mother with new-onset anti-MuSK-mediated myasthenia gravis. , 2009, Journal of clinical neuromuscular disease.
[224] M. Benatar,et al. The muddle of mycophenolate mofetil in myasthenia , 2008, Neurology.